MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ajh.27246

Медицинская библиотека · American journal of hematology · 2024

Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.

Pratz Keith W, Jonas Brian A, Pullarkat Vinod, Thirman Michael J, Garcia Jacqueline S, Döhner Hartmut, Récher Christian, Fiedler Walter, Yamamoto Kazuhito, Wang Jianxiang, Yoon Sung-Soo, Wolach Ofir, Yeh Su-Peng, Leber Brian, Esteve Jordi, Mayer Jiri, Porkka Kimmo, Illés Árpád, Lemoli Roberto M, Turgut Mehmet, Ku Grace, Miller Catherine, Zhou Ying, Zhang Meng, Chyla Brenda, Potluri Jalaja, DiNardo Courtney D

Рандомизированное исследованиеСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Venetoclax-azacitidine is approved for treatment of patients with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive chemotherapy based on the interim overall survival (OS) analysis of the VIALE-A study (NCT02993523). Here, long-term follow-up is presented to address survival benefit and long-term outcomes with venetoclax-azacitidine. Patients with newly diagnosed AML who were ineligible for intensive chemotherapy were randomized 2:1 to receive venetoclax-azacitidine or placebo-azacitidine. OS was the primary endpoint; complete remission with/without blood count recovery (CR/CRi) was a key secondary endpoint. This final analysis was conducted when 100% of the predefined 360 OS events occurred. In VIALE-A, 431 patients were enrolled to venetoclax-azacitidine (n = 286) or placebo-azacitidine (n = 145). At 43.2 months median follow-up, median OS was 14.7 months (95% confidence interval [CI], 12.1-18.7) with venetoclax-azacitidine, and 9.6 months (95% CI, 7.4-12.7) with placebo-azacitidine (hazard ratio, 0.58 [95% CI, 0.47-0.72], p < .001); the estimated 24-month OS rate was 37.5% and 16.9%, respectively. Median OS for patients with IDH1/2 mutations and those with measurable residual disease responses was reached in this final analysis. CR/CRi rate was similar to interim analysis. Any-grade hematologic and gastrointestinal adverse events were most common in venetoclax-azacitidine and placebo-azacitidine arms, including thrombocytopenia (47% and 42%) and neutropenia (43% and 29%). No new safety signals were identified. Long-term efficacy and safety confirm venetoclax-azacitidine is an improvement in standard-of-care for patients with AML who are not eligible for intensive chemotherapy because of advanced age or comorbidities.

Для цитирования: Pratz Keith W, Jonas Brian A, Pullarkat Vinod, Thirman Michael J, Garcia Jacqueline S, Döhner Hartmut, Récher Christian, Fiedler Walter, Yamamoto Kazuhito, Wang Jianxiang, Yoon Sung-Soo, Wolach Ofir, Yeh Su-Peng, Leber Brian, Esteve Jordi, Mayer Jiri, Porkka Kimmo, Illés Árpád, Lemoli Roberto M, Turgut Mehmet, Ku Grace, Miller Catherine, Zhou Ying, Zhang Meng, Chyla Brenda, Potluri Jalaja, DiNardo Courtney D. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.. American journal of hematology. 2024. DOI: 10.1002/ajh.27246.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.